Insmed Incorporated Share Price & Technical Analysis
INSM · $106.2 (-3.00%)
Healthcare / Biotechnology
$106.2
-3.00%
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibac…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-22% return in May, 38% avg return in past 3 year May month.
-43% return in 2026, 95% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -11% | -5% | 11% | -17% | -22% | – | – | – | – | – | – | – | -43% |
| 25 | 9% | 9% | -6% | -4% | -3% | 44% | 7% | 27% | 2% | 31% | 11% | -16% | 110% |
| 24 | -10% | -1% | -3% | -8% | 119% | 22% | 10% | 5% | -6% | -8% | 11% | -8% | 124% |
| 23 | 7% | -5% | -17% | 15% | -2% | 10% | 5% | 0% | 15% | 0% | -1% | 24% | 50% |
| 22 | -17% | 5% | -1% | -7% | -15% | 5% | 12% | 12% | -12% | -21% | 6% | 7% | -27% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$24.76B
P/E ratio
—
52W high
$212.8
52W low
$65.56
Volume
24,32,892
Beta
0.89
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Insmed Incorporated share price today?
- Insmed Incorporated (INSM) last traded around $106.2 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does INSM have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for INSM. Download the app for real-time alerts.
- How can I analyze Insmed Incorporated stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.